COMMUNIQUÉS West-GlobeNewswire

TOMI Environmental Solutions’ Binary Ionization Technology Approved in the Netherlands
25/03/2026
European Union Market Expansion Advances with Official Authorization FREDERICK, Md., March 25, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and [...]
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
25/03/2026
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-5 reverse split of its [...]
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
25/03/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
25/03/2026
CRANFORD, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has completed its previously announced exchange offer to each holder of [...]
ORYZON Strengthens Vafidemstat Patent Portfolio With U.S. Notice of Allowance
25/03/2026
Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD) MADRID, and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015 [...]
Eascra Biotech Takes First Place at TechConnect Bio in Space Innovation Challenge
25/03/2026
Nanomedicine startup wins $30,000 prize for pioneering nanoparticle delivery platform BOSTON, March 25, 2026 (GLOBE NEWSWIRE) -- Eascra Biotech , a nanomedicine startup, has won first place at the TechConnect Bio in [...]
Declaration de NANOBIOTIX concernant une recente rumeur mediatique
25/03/2026
PARIS, FRANCE; CAMBRIDGE, Massachusetts, 25 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société » ), société française de biotechnologie en phase de développement clinique avancé, [...]
HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
25/03/2026
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing [...]
Verano to Report First Quarter 2026 Financial Results on April 30, 2026
25/03/2026
CHICAGO, March 25, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
25/03/2026
Rejects Allegations of MindWave Innovations, Inc. SEOUL, South Korea, March 25, 2026 (GLOBE NEWSWIRE) -- Inscobee Inc. (“Inscobee”) and Apimeds, Inc., (“Apimeds Korea”) today announced that on March 20, 2026, Inscobee [...]
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
25/03/2026
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical [...]
NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
25/03/2026
The collaboration aims to uncover clinically actionable patient subpopulations and biomarker-driven treatment insights from a landmark precision-oncology trial TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark [...]
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
25/03/2026
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8: [...]
Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers
25/03/2026
VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- Algernon Health Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to introduce NovaScan Neuroimaging Clinics TM as [...]
Tilray Brands to Announce Third Quarter Fiscal Year 2026 Financial Results on April 1, 2026
25/03/2026
NEW YORK and LEAMINGTON, Ontario, March 25, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of [...]
Picard Medical Reports Full Year 2025 Financial Results
25/03/2026
Revenue Growth and Continued Adoption of SynCardia Total Artificial Heart TUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems [...]
Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)
25/03/2026
– TEV ‘325, which targets IL-13 and TSLP, is being studied for the treatment of TH2-driven inflammatory diseases such as asthma and atopic dermatitis – TEV ‘325 was computationally designed using Biolojic’s Multibody [...]
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
25/03/2026
– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated – – The subgroup of [...]
Cellbricks Therapeutics Raises €10 Million New Capital to Move Living Tissue Implants Toward the Clinic
25/03/2026
Funding will accelerate preclinical validation of biofabricated tissue implants for soft tissue repair, wound healing and trauma care - while building the biological and manufacturing foundations for 3D-bioprinted [...]

Pages